{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.4","upperLimit":"81.2","value":"76.6"},{"groupId":"OG001","lowerLimit":"81.3","upperLimit":"89.5","value":"85.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"302"}],"units":"Participants"}],"description":"Disease Control Rate is defined as the percentage of all randomized participants whose Best Overall Response was complete response (CR), partial response (PR), stable disease (SD) or Non-CR/Non-PD as assessed by Blinded Independent Central Review (BICR). Per adapted m-RECIST for pleural mesothelioma, each single tumor measurement must be at least 10 mm in length to qualify as measureable disease and contribute to the sum that defines the pleural uni-variate measure. Per RECIST 1.1 for solid tumors, confirmation of response required:\n\nCR=Disappearance of all target lesions; PR=At least a 30% decrease in the sum of the Total Tumor Measurement; Progressive disease (PD)=At least a 20% increase in the sum of the Total Tumor Measurement; SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Non-CR/Non-PD: Persistence of one or more non-target lesion(s).","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV Q2W + Ipilimumab 1 mg/kg IV Q6W","id":"OG000","title":"Treatment A"},{"description":"Pemetrexed 500 mg/m\\^2 + Cisplatin 75 mg/m\\^2 or Carboplatin 5 AUC up to 6 cycles","id":"OG001","title":"Treatment B"}],"paramType":"NUMBER","populationDescription":"All Randomized Participants","reportingStatus":"POSTED","timeFrame":"From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}